Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?

Medeni S. S., Turkyilmaz D., Acar C., Sevindik O. G., YÜKSEL F., Piskin O., ...More

TURKISH JOURNAL OF HEMATOLOGY, vol.35, no.4, pp.271-276, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.4274/tjh.2018.0071
  • Journal Name: TURKISH JOURNAL OF HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.271-276
  • Keywords: Multiple myeloma, Autologous transplantation, Multiple reinfusion days, MYELOMA PATIENTS, AUTOLOGOUS TRANSPLANTATION, BLOOD, RECOVERY, OLDER, AGE, CHEMOTHERAPY, EXPERIENCE, MANAGEMENT, RELEVANCE
  • Dokuz Eylül University Affiliated: Yes

Abstract

Objective: High-doses of melphalan treatment with autologous stem cell transplantation in multiple myeloma (MM) remains a major treatment modality in suitable patients. A minimal dose of 2x10(6)/kg CD34+ cells is preferred to achieve engraftment. Some patients need multiple leukapheresis procedures to achieve the necessary number of CD34+ cells, but this can cause a high volume of stem cell product that cannot be given in a single day. Whether or not the number of infusion days affects engraftment has not been studied before. We aimed to evaluate the impact of reinfusion of stem cells on multiple days on engraftment results.